InFocus Capital Partners

InFocus Capital Partners is a specialized life sciences venture fund formed by ophthalmologists to back early-stage vision and eye care therapeutics. Headquartered in Philadelphia, the firm reflects a model where physician-investors make capital allocation decisions in a category they practice in daily. Founders working on ophthalmic drug delivery, novel small molecules and biologics for retinal disease, glaucoma therapeutics, dry eye treatments, ocular surface disease, gene therapy for inherited retinal diseases, and ophthalmic medical devices that complement therapeutic strategies fit the thesis.

The fund invests at Seed and Series A with check sizes of $250k to $1M, making it among the earlier-stage and smaller-check ophthalmology specialists in this batch. It is based in the United States and operates across medical devices and MedTech and pharma and therapeutics. There is no stated AI focus.

Founders should arrive with a clear scientific rationale, preclinical or early clinical data where applicable, a defined regulatory pathway, and a thoughtful capital plan for translating early ophthalmology science into a fundable Series A. The physician-led structure means scientific diligence will be rigorous and clinically grounded. Limited public information is available about all named partners and complete portfolio. Introductions via academic ophthalmology departments, retinal subspecialty networks, and the firm’s website are typical entry paths.